Symbols / ARTL Stock $4.00 -1.23% Artelo Biosciences, Inc.
ARTL (Stock) Chart
About
Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. The company's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of cancer-related anorexia; and ART12.11, a cocrystal composition of cannabidiol and tetramethylpyrazine for the treatment anxiety, depression, post-traumatic stress disorder PTSD, epilepsy and insomnia, and other potential indications. It also offers ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders. The company was formerly known as Reactive Medical Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.
Stock Fundamentals
Scroll to Statements| Market Cap | 3.75M | Enterprise Value | 2.91M | Income | -12.88M | Sales | — | Book/sh | -1.89 | Cash/sh | 0.85 |
| Dividend Yield | — | Payout | 0.00% | Employees | 7 | IPO | — | P/E | — | Forward P/E | -4.55 |
| PEG | — | P/S | — | P/B | -2.12 | P/C | — | EV/EBITDA | — | EV/Sales | — |
| Quick Ratio | 0.15 | Current Ratio | 0.17 | Debt/Eq | — | LT Debt/Eq | — | EPS (ttm) | -37.56 | EPS next Y | -0.88 |
| EPS Growth | — | Revenue Growth | — | Earnings | 2026-02-24 | ROA | -190.09% | ROE | -16.25% | ROIC | — |
| Gross Margin | 0.00% | Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 938.13K | Shs Float | 644.70K | Short Float | 57.94% |
| Short Ratio | 0.06 | Short Interest | — | 52W High | 85.80 | 52W Low | 2.96 | Beta | 0.41 | Avg Volume | 3.44M |
| Volume | 619.03K | Target Price | — | Recom | None | Prev Close | $4.05 | Price | $4.00 | Change | -1.23% |
Valuation Models
Price estimates from analyst targets and simple models.
Ratings
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-11-19 | down | Maxim Group | Buy → Hold | — |
| 2025-09-08 | down | D. Boral Capital | Buy → Hold | — |
| 2025-08-26 | main | D. Boral Capital | Buy → Buy | $18 |
| 2025-08-18 | main | D. Boral Capital | Buy → Buy | $18 |
| 2025-08-06 | main | D. Boral Capital | Buy → Buy | $18 |
| 2025-08-04 | main | D. Boral Capital | Buy → Buy | $18 |
| 2025-07-08 | up | D. Boral Capital | Hold → Buy | $20 |
| 2025-06-11 | down | D. Boral Capital | Buy → Hold | — |
| 2025-06-06 | main | D. Boral Capital | Buy → Buy | $6 |
| 2025-04-28 | main | D. Boral Capital | Buy → Buy | $6 |
| 2025-04-02 | main | D. Boral Capital | Buy → Buy | $6 |
| 2025-03-04 | reit | HC Wainwright & Co. | Buy → Buy | $5 |
| 2025-03-03 | main | D. Boral Capital | Buy → Buy | $6 |
| 2025-02-27 | main | D. Boral Capital | Buy → Buy | $6 |
| 2025-01-14 | main | D. Boral Capital | Buy → Buy | $6 |
| 2024-12-09 | main | D. Boral Capital | Buy → Buy | $6 |
| 2024-12-09 | reit | HC Wainwright & Co. | Buy → Buy | $5 |
| 2024-08-14 | reit | HC Wainwright & Co. | Buy → Buy | $5 |
| 2024-06-05 | reit | HC Wainwright & Co. | Buy → Buy | $5 |
| 2024-05-15 | reit | HC Wainwright & Co. | Buy → Buy | $5 |
- Artelo says non-opioid pain drug had no serious drug-related events - Stock Titan Mon, 20 Apr 2026 11
- Artelo (ARTL) Stock Fundamentals | Q4 2025: EPS Exceeds Expectations - Social Trading Insights - Cổng thông tin điện tử Tỉnh Sơn La hu, 23 Apr 2026 02
- ARTL Stock Draws Traders As Biotech Pipeline Expands - timothysykes.com Mon, 20 Apr 2026 15
- ARTL Stock In Play As Pipeline Expands And Nasdaq Risk Eases - StocksToTrade Mon, 20 Apr 2026 15
- ARTL (Artelo Biosciences Inc.) delivers 97.5 percent positive Q4 2025 EPS surprise, but shares drop 8.64 percent today. - Cổng thông tin điện tử tỉnh Tây Ninh Wed, 22 Apr 2026 20
- What's Behind The Rise In Artelo Biosciences Stock? - Benzinga Mon, 20 Apr 2026 16
- Why Is ARTL Stock Soaring Today? - Stocktwits Wed, 18 Mar 2026 12
- Artelo Biosciences Soars 230% on Obesity Push — Why Is ARTL Stock Now Crashing? - TipRanks Mon, 30 Mar 2026 07
- ARTL Stock Whipsaws As Artelo Biosciences Expands High-Risk, High-Reward Pipeline - timothysykes.com Mon, 20 Apr 2026 13
- $11M Artelo stock sale targets debt repayment, working capital - Stock Titan Fri, 27 Mar 2026 07
- Why Is ARTL Stock Soaring Today? - Stocktwits ue, 07 Apr 2026 07
- Artelo takes its lead drug into glaucoma without paying for the trial - Stock Titan Wed, 25 Mar 2026 07
- GLP-1 weight loss can cut lean mass; Artelo starts protection study - Stock Titan Wed, 25 Mar 2026 07
- Artelo shrinks share count to 708K in 3-for-1 reverse split - Stock Titan Fri, 06 Mar 2026 08
- [RW] ARTELO BIOSCIENCES, INC. SEC Filing - Stock Titan Fri, 27 Mar 2026 07
Financials
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Expense |
|
11.40
+12.82%
|
10.11
+1.79%
|
9.93
-3.47%
|
10.29
|
| Research And Development |
|
5.42
-9.51%
|
5.99
+5.21%
|
5.70
+31.73%
|
4.32
|
| Selling General And Administration |
|
5.98
+45.35%
|
4.12
-2.81%
|
4.23
-29.00%
|
5.96
|
| General And Administrative Expense |
|
5.98
+45.35%
|
4.12
-2.81%
|
4.23
-29.00%
|
5.96
|
| Other Gand A |
|
5.98
+45.35%
|
4.12
-2.81%
|
4.23
-29.00%
|
5.96
|
| Total Expenses |
|
11.40
+12.82%
|
10.11
+1.79%
|
9.93
-3.47%
|
10.29
|
| Operating Income |
|
-11.40
-12.82%
|
-10.11
-1.79%
|
-9.93
+3.47%
|
-10.29
|
| Total Operating Income As Reported |
|
-11.40
-12.82%
|
-10.11
-1.79%
|
-9.93
+3.47%
|
-10.29
|
| EBITDA |
|
-12.60
-28.25%
|
-9.83
+1.05%
|
-9.93
+1.47%
|
-10.08
|
| Normalized EBITDA |
|
-11.40
-12.82%
|
-10.11
+4.38%
|
-10.57
-2.78%
|
-10.29
|
| EBIT |
|
-12.60
-28.25%
|
-9.83
+1.05%
|
-9.93
+1.47%
|
-10.08
|
| Total Unusual Items |
|
-1.20
-524.82%
|
0.28
-56.01%
|
0.64
+209.66%
|
0.21
|
| Total Unusual Items Excluding Goodwill |
|
-1.20
-524.82%
|
0.28
-56.01%
|
0.64
+209.66%
|
0.21
|
| Special Income Charges |
|
-1.16
|
0.00
|
—
|
—
|
| Other Special Charges |
|
1.16
|
—
|
—
|
—
|
| Net Income |
|
-12.88
-31.07%
|
-9.83
-5.78%
|
-9.29
+7.87%
|
-10.08
|
| Pretax Income |
|
-12.88
-31.07%
|
-9.83
-5.78%
|
-9.29
+7.87%
|
-10.08
|
| Net Non Operating Interest Income Expense |
|
-0.28
|
0.00
|
0.00
+100.00%
|
-0.00
|
| Interest Expense Non Operating |
|
0.28
|
0.00
|
0.00
-100.00%
|
0.01
|
| Net Interest Income |
|
-0.28
|
0.00
|
0.00
+100.00%
|
-0.00
|
| Interest Expense |
|
0.28
|
0.00
|
0.00
-100.00%
|
0.01
|
| Interest Income Non Operating |
|
—
|
—
|
0.00
-100.00%
|
0.00
|
| Interest Income |
|
—
|
—
|
0.00
-100.00%
|
0.00
|
| Other Income Expense |
|
-1.20
-524.82%
|
0.28
-56.01%
|
0.64
+209.66%
|
0.21
|
| Gain On Sale Of Security |
|
-0.04
-114.18%
|
0.28
-56.01%
|
0.64
+209.66%
|
0.21
|
| Tax Provision |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Tax Rate For Calcs |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-12.88
-31.07%
|
-9.83
-5.78%
|
-9.29
+7.87%
|
-10.08
|
| Net Income From Continuing Operation Net Minority Interest |
|
-12.88
-31.07%
|
-9.83
-5.78%
|
-9.29
+7.87%
|
-10.08
|
| Net Income From Continuing And Discontinued Operation |
|
-12.88
-31.07%
|
-9.83
-5.78%
|
-9.29
+7.87%
|
-10.08
|
| Net Income Continuous Operations |
|
-12.88
-31.07%
|
-9.83
-5.78%
|
-9.29
+7.87%
|
-10.08
|
| Normalized Income |
|
-11.68
-15.56%
|
-10.11
-1.79%
|
-9.93
+3.50%
|
-10.29
|
| Net Income Common Stockholders |
|
-12.88
-31.07%
|
-9.83
-5.78%
|
-9.29
+7.87%
|
-10.08
|
| Diluted EPS |
|
—
|
-54.90
+2.87%
|
-56.52
+11.80%
|
-64.08
|
| Basic EPS |
|
—
|
-54.90
+2.87%
|
-56.52
+11.80%
|
-64.08
|
| Basic Average Shares |
|
—
|
0.18
+8.85%
|
0.16
+4.48%
|
0.16
|
| Diluted Average Shares |
|
—
|
0.18
+8.85%
|
0.16
+4.48%
|
0.16
|
| Diluted NI Availto Com Stockholders |
|
-12.88
-31.07%
|
-9.83
-5.78%
|
-9.29
+7.87%
|
-10.08
|
| Line Item | Trend | 2023-12-31 |
|---|---|---|
| Total Assets |
|
13.04
|
| Current Assets |
|
10.98
|
| Cash Cash Equivalents And Short Term Investments |
|
10.43
|
| Cash And Cash Equivalents |
|
2.81
|
| Other Short Term Investments |
|
7.61
|
| Prepaid Assets |
|
—
|
| Other Current Assets |
|
0.55
|
| Total Non Current Assets |
|
2.06
|
| Net PPE |
|
0.02
|
| Gross PPE |
|
0.02
|
| Properties |
|
0.00
|
| Buildings And Improvements |
|
0.02
|
| Other Properties |
|
0.02
|
| Goodwill And Other Intangible Assets |
|
2.04
|
| Other Intangible Assets |
|
2.04
|
| Investments And Advances |
|
—
|
| Non Current Prepaid Assets |
|
—
|
| Other Non Current Assets |
|
0.00
|
| Total Liabilities Net Minority Interest |
|
1.29
|
| Current Liabilities |
|
1.29
|
| Payables And Accrued Expenses |
|
1.27
|
| Payables |
|
1.27
|
| Accounts Payable |
|
1.24
|
| Current Accrued Expenses |
|
—
|
| Current Debt And Capital Lease Obligation |
|
0.02
|
| Current Debt |
|
—
|
| Other Current Borrowings |
|
—
|
| Current Capital Lease Obligation |
|
0.02
|
| Other Current Liabilities |
|
—
|
| Total Non Current Liabilities Net Minority Interest |
|
0.00
|
| Long Term Debt And Capital Lease Obligation |
|
0.00
|
| Long Term Capital Lease Obligation |
|
0.00
|
| Stockholders Equity |
|
11.75
|
| Common Stock Equity |
|
11.75
|
| Capital Stock |
|
0.00
|
| Common Stock |
|
0.00
|
| Preferred Stock |
|
0.00
|
| Share Issued |
|
0.18
|
| Ordinary Shares Number |
|
0.18
|
| Treasury Shares Number |
|
0.00
|
| Additional Paid In Capital |
|
52.26
|
| Retained Earnings |
|
-40.31
|
| Gains Losses Not Affecting Retained Earnings |
|
-0.20
|
| Other Equity Adjustments |
|
-0.20
|
| Total Equity Gross Minority Interest |
|
11.75
|
| Total Capitalization |
|
11.75
|
| Working Capital |
|
9.69
|
| Invested Capital |
|
11.75
|
| Total Debt |
|
0.02
|
| Net Debt |
|
—
|
| Capital Lease Obligations |
|
0.02
|
| Net Tangible Assets |
|
9.71
|
| Tangible Book Value |
|
9.71
|
| Dueto Related Parties Current |
|
0.03
|
| Interest Payable |
|
—
|
| Investmentin Financial Assets |
|
—
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-8.52
-2.04%
|
-8.35
-1.74%
|
-8.21
-2.49%
|
-8.01
|
| Cash Flow From Continuing Operating Activities |
|
-8.52
-2.04%
|
-8.35
-1.74%
|
-8.21
-2.49%
|
-8.01
|
| Net Income From Continuing Operations |
|
-12.88
-31.07%
|
-9.83
-5.78%
|
-9.29
+7.87%
|
-10.08
|
| Other Non Cash Items |
|
0.21
+6833.33%
|
0.00
|
—
|
-0.00
|
| Stock Based Compensation |
|
1.14
+39.61%
|
0.82
-19.80%
|
1.02
-58.50%
|
2.46
|
| Operating Gains Losses |
|
1.22
|
—
|
—
|
—
|
| Gain Loss On Investment Securities |
|
0.06
|
—
|
—
|
—
|
| Unrealized Gain Loss On Investment Securities |
|
0.00
+100.00%
|
-0.28
+56.01%
|
-0.64
-209.66%
|
-0.21
|
| Change In Working Capital |
|
1.79
+90.93%
|
0.94
+33.29%
|
0.70
+508.72%
|
-0.17
|
| Change In Prepaid Assets |
|
0.13
-71.77%
|
0.46
+6.28%
|
0.43
+320.51%
|
-0.20
|
| Change In Payables And Accrued Expense |
|
1.66
+245.83%
|
0.48
+75.82%
|
0.27
+1086.96%
|
0.02
|
| Change In Accrued Expense |
|
0.07
|
0.00
|
—
|
—
|
| Change In Payable |
|
1.59
+231.46%
|
0.48
+75.82%
|
0.27
+1086.96%
|
0.02
|
| Change In Account Payable |
|
1.59
+231.46%
|
0.48
+75.82%
|
0.27
+1086.96%
|
0.02
|
| Investing Cash Flow |
|
-0.06
-100.80%
|
7.77
+121.53%
|
3.51
+18.56%
|
2.96
|
| Cash Flow From Continuing Investing Activities |
|
-0.06
-100.80%
|
7.77
+121.53%
|
3.51
+18.56%
|
2.96
|
| Net Investment Purchase And Sale |
|
-0.06
-100.80%
|
7.77
+121.53%
|
3.51
+18.56%
|
2.96
|
| Purchase Of Investment |
|
-0.25
+48.02%
|
-0.48
+96.49%
|
-13.69
-3.49%
|
-13.22
|
| Sale Of Investment |
|
0.19
-97.72%
|
8.25
-52.01%
|
17.19
+6.24%
|
16.18
|
| Financing Cash Flow |
|
6.87
+6031.25%
|
0.11
-80.25%
|
0.57
|
0.00
|
| Cash Flow From Continuing Financing Activities |
|
6.87
+6031.25%
|
0.11
-80.25%
|
0.57
|
0.00
|
| Net Issuance Payments Of Debt |
|
0.58
|
0.00
|
—
|
—
|
| Issuance Of Debt |
|
0.61
|
0.00
|
—
|
—
|
| Repayment Of Debt |
|
-0.02
|
0.00
|
—
|
—
|
| Short Term Debt Issuance |
|
0.61
|
0.00
|
—
|
—
|
| Short Term Debt Payments |
|
-0.02
|
0.00
|
—
|
—
|
| Net Short Term Debt Issuance |
|
0.58
|
0.00
|
—
|
—
|
| Net Common Stock Issuance |
|
6.15
+5391.96%
|
0.11
-80.25%
|
0.57
|
0.00
|
| Proceeds From Stock Option Exercised |
|
0.13
|
0.00
|
—
|
0.00
|
| Net Other Financing Charges |
|
—
|
—
|
—
|
—
|
| Changes In Cash |
|
-1.72
-265.67%
|
-0.47
+88.65%
|
-4.13
+18.16%
|
-5.05
|
| Effect Of Exchange Rate Changes |
|
-0.02
-187.50%
|
-0.01
-113.33%
|
0.06
+126.79%
|
-0.22
|
| Beginning Cash Position |
|
2.34
-16.94%
|
2.81
-59.13%
|
6.89
-43.36%
|
12.16
|
| End Cash Position |
|
0.60
-74.34%
|
2.34
-16.94%
|
2.81
-59.13%
|
6.89
|
| Free Cash Flow |
|
-8.52
-2.04%
|
-8.35
-1.74%
|
-8.21
-2.49%
|
-8.01
|
| Interest Paid Supplemental Data |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Income Tax Paid Supplemental Data |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Change In Interest Payable |
|
0.07
|
0.00
|
—
|
—
|
| Common Stock Issuance |
|
6.15
+5391.96%
|
0.11
-80.25%
|
0.57
|
0.00
|
| Issuance Of Capital Stock |
|
6.15
+5391.96%
|
0.11
-80.25%
|
0.57
|
0.00
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 8-K2026-04-07 View
- 8-K2026-03-30 View
- 8-K2026-03-26 View
- 8-K2026-03-18 View
- 8-K2026-03-17 View
- 8-K2026-03-06 View
- 10-K2026-02-24 View
- 8-K2026-02-05 View
- 8-K2026-02-05 View
- 42026-02-02 View
- 42026-02-02 View
- 42026-02-02 View
- 42026-02-02 View
- 42026-02-02 View
- 42026-02-02 View
- 42026-02-02 View
- 42026-02-02 View
- 8-K2026-01-30 View
- 8-K2026-01-16 View
- 8-K2026-01-02 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|